- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Date: Thursday, November 13, 2025 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conference Call Number: 1-833-630-1956 International Call Number: +1-412-317-1837 ...

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events ...

(Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of ...

Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity Research at ...

Conference Call and Webcast scheduled for tomorrow, November 4, 2025 at 10:00 am PT. SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ...

Brian Coleman has led Hudson Technologies as Chairman, President and Chief Executive Officer since June 2020. He joined Hudson Technologies as Chief Financial Officer in 1997 and was later appointed ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile (GEP) test ...

RENO, Nev., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading renewable energy company, today announced financial results for the third ...

Third Quarter 2025 Highlights 1: Combined ratio of 94.0% as compared to 135.5% in the prior year quarter. Underwriting income of $8.9 million as compared to a loss of $56.8 million in the prior year ...

Delivery and handling costs decreased by 14% to $1.1 million during the third quarter of 2025 compared to $1.3 million in the third quarter of 2024, primarily driven by lower transportation costs.

Glucotrack strongly encourages all shareholders to vote their shares as soon as possible. The shareholder vote provides, in compliance with NASDAQ Listing Rule 5635 (d), the ability to issue more than ...